JP2012523376A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012523376A5 JP2012523376A5 JP2011552217A JP2011552217A JP2012523376A5 JP 2012523376 A5 JP2012523376 A5 JP 2012523376A5 JP 2011552217 A JP2011552217 A JP 2011552217A JP 2011552217 A JP2011552217 A JP 2011552217A JP 2012523376 A5 JP2012523376 A5 JP 2012523376A5
- Authority
- JP
- Japan
- Prior art keywords
- sns
- pharmaceutical composition
- composition according
- cancer
- dose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- XZAFZXJXZHRNAQ-STQMWFEESA-N Vosaroxin Chemical compound C1[C@H](OC)[C@@H](NC)CN1C1=CC=C2C(=O)C(C(O)=O)=CN(C=3SC=CN=3)C2=N1 XZAFZXJXZHRNAQ-STQMWFEESA-N 0.000 claims 21
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 201000011510 cancer Diseases 0.000 claims 11
- 102000002280 BRCA2 Protein Human genes 0.000 claims 9
- 108010000750 BRCA2 Protein Proteins 0.000 claims 9
- 230000035772 mutation Effects 0.000 claims 7
- 239000012472 biological sample Substances 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 101700007241 APOC4 Proteins 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 102100013894 BCL2 Human genes 0.000 claims 1
- 108060000885 BCL2 Proteins 0.000 claims 1
- 210000001124 Body Fluids Anatomy 0.000 claims 1
- 102000015550 Cyclin-dependent kinase inhibitor Human genes 0.000 claims 1
- 108050004829 Cyclin-dependent kinase inhibitor Proteins 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 Dexamethasone Drugs 0.000 claims 1
- -1 EGFR inhibitors Proteins 0.000 claims 1
- 229940121647 EGFR inhibitors Drugs 0.000 claims 1
- 229940110715 ENZYMES FOR TREATMENT OF WOUNDS AND ULCERS Drugs 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 229940114721 Enzymes FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM Drugs 0.000 claims 1
- 229940093738 Enzymes for ALIMENTARY TRACT AND METABOLISM Drugs 0.000 claims 1
- 101710038729 F2R Proteins 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 102100013180 KDR Human genes 0.000 claims 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 101700036247 PARP1 Proteins 0.000 claims 1
- 102100014579 PARP1 Human genes 0.000 claims 1
- 101700053624 PARP2 Proteins 0.000 claims 1
- 101700027237 PROA Proteins 0.000 claims 1
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 1
- 231100000614 Poison Toxicity 0.000 claims 1
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims 1
- 231100000765 Toxin Toxicity 0.000 claims 1
- 108091007928 VEGF receptors Proteins 0.000 claims 1
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 claims 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 230000000259 anti-tumor Effects 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940019336 antithrombotic Enzymes Drugs 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 101700004528 arp Proteins 0.000 claims 1
- 239000003719 aurora kinase inhibitor Substances 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 239000010839 body fluid Substances 0.000 claims 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 229940020899 hematological Enzymes Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 239000002944 hormone and hormone analog Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 229910001410 inorganic ion Inorganic materials 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 230000000394 mitotic Effects 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 229940083249 peripheral vasodilators Enzymes Drugs 0.000 claims 1
- 239000002574 poison Substances 0.000 claims 1
- 239000003207 proteasome inhibitor Substances 0.000 claims 1
- 239000000649 purine antagonist Substances 0.000 claims 1
- 239000003790 pyrimidine antagonist Substances 0.000 claims 1
- 210000001519 tissues Anatomy 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 claims 1
Claims (22)
- SNS-595を含む、BRCA2活性を低下させるBRCA2変異を有する対象の癌を治療するための医薬組成物であって、SNS-595が10〜100mg/m2の投与量で投与されるように用いられることを特徴とする、前記医薬組成物。
- 前記癌が、乳癌、卵巣癌、前立腺癌、又は膵臓癌である、請求項１記載の医薬組成物。
- 前記癌が乳癌である、請求項２記載の医薬組成物。
- 前記対象が、999del5、6174delT、8803delC、4486delG、5445del5、2024del5、763insAT、763insAT、983delACAG、A3058T、3758delACAG、3908delTG、4706delAAAG、5804delTTAA、C6137A、6174delT、6305insA、9132delC、del2352ins12、dup9700、及びdel1518から選択されるBRCA2変異を有する、請求項１記載の医薬組成物。
- SNS-595が40〜90mg/m2の投与量で投与されるように用いられることを特徴とする、請求項１〜４のいずれか１項記載の医薬組成物。
- SNS-595が30〜60mg/m2の投与量で投与されるように用いられることを特徴とする、請求項１〜４のいずれか１項記載の医薬組成物。
- i)40〜90mg/m2の投与量のSNS-595を対象に投与すること；ii)SNS-595を対象に投与しないで、少なくとも6日間待機すること；及びiii)40〜90mg/m2の別の投与量のSNS-595を対象に投与することを含む投与計画に従って使用されることを特徴とする、請求項１〜４のいずれか１項記載の医薬組成物。
- 前記投与量が、10mg/m2、15mg/m2、18mg/m2、21mg/m2、24mg/m2、30mg/m2、35mg/m2、40mg/m2、45mg/m2、48mg/m2、50mg/m2、60mg/m2、72mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、又は100mg/m2である、請求項１〜４のいずれか１項記載の医薬組成物。
- 前記投与量のSNS-595が3週間に1回投与されるように用いられることを特徴とする、請求項１〜８のいずれか１項記載の医薬組成物。
- 前記投与量のSNS-595が4週間に1回投与されるように用いられることを特徴とする、請求項１〜８のいずれか１項記載の医薬組成物。
- SNS-595が、3週間に1回、48mg/m2の投与量で投与されるように用いられることを特徴とする、請求項１〜８のいずれか１項記載の医薬組成物。
- SNS-595が、4週間に1回、60mg/m2の投与量で投与されるように用いられることを特徴とする、請求項１〜８のいずれか１項記載の医薬組成物。
- SNS-595が、4週間に1回、75mg/m2の投与量で投与されるように用いられることを特徴とする、請求項１〜５のいずれか１項記載の医薬組成物。
- SNS-595がIV注射として投与されるように用いられることを特徴とする、請求項１〜１３のいずれか１項記載の医薬組成物。
- SNS-595が、少なくとも1種の他の治療薬と共投与されるように用いられることを特徴とする、請求項１〜１４のいずれか１項記載の医薬組成物。
- 前記少なくとも１種の他の治療薬が、アルキル化剤、代謝拮抗剤、オーロラキナーゼ阻害剤、プリンアンタゴニスト、ピリミジンアンタゴニスト、紡錘体毒、分裂抑制因子、トポイソメラーゼII阻害剤及び毒、トポイソメラーゼI阻害剤、抗腫瘍性抗生物質、ニトロソウレア、無機イオン錯体、酵素、ホルモン及びホルモン類似体、EGFR阻害剤、抗体及び抗体誘導体、IMID、HDAC阻害剤、Bcl-2阻害剤、VEGF-刺激チロシンキナーゼ阻害剤、VEGFR阻害剤、プロテアソーム阻害剤、サイクリン依存性キナーゼ阻害剤、PARP阻害剤、アロマターゼ阻害剤、及びデキサメタゾンから選択される、請求項１５記載の医薬組成物。
- 前記治療薬が対症療法剤である、請求項１５記載の医薬組成物。
- (a)癌を有する候補者から得られた生物学的試料を用意すること；(b)BRCA2変異について、生物学的試料をスクリーニングすること；及び(c)該候補者がBRCA2の活性を低下させる変異を有する場合に、該候補者をSNS-595により治療するのに適した癌対象と特定することを含む、SNS-595により治療するのに適した癌対象の特定方法。
- (a)癌を有する複数の候補者から得られた生物学的試料を用意すること；(b)BRCA2変異について、生物学的試料をスクリーニングすること；及び(c)SNS-595により治療するのに適した癌対象としてBRCA2変異を有する各候補者を特定することを含む、SNS-595により治療するのに適した、1人以上の癌対象の特定方法。
- 前記生物学的試料が、体液試料又は組織試料を含む、請求項１８又は１９記載の方法。
- SNS-595を含む、BRCA2活性を低下させる変異を有する癌細胞において二重鎖DNA切断を引き起こすための医薬組成物。
- SNS-595を含む、BRCA2活性が低下した対象の癌を治療するための医薬組成物であって、SNS-595が10〜100mg/m2の投与量で投与されるように用いられることを特徴とする、前記医薬組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15644909P | 2009-02-27 | 2009-02-27 | |
| US61/156,449 | 2009-02-27 | ||
| US17001309P | 2009-04-16 | 2009-04-16 | |
| US61/170,013 | 2009-04-16 | ||
| PCT/US2010/025737 WO2010099526A1 (en) | 2009-02-27 | 2010-03-01 | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015060900A Division JP2015145396A (ja) | 2009-02-27 | 2015-03-24 | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012523376A JP2012523376A (ja) | 2012-10-04 |
| JP2012523376A5 true JP2012523376A5 (ja) | 2013-04-18 |
| JP5936862B2 JP5936862B2 (ja) | 2016-06-22 |
Family
ID=42224275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011552217A Expired - Fee Related JP5936862B2 (ja) | 2009-02-27 | 2010-03-01 | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
| JP2015060900A Pending JP2015145396A (ja) | 2009-02-27 | 2015-03-24 | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015060900A Pending JP2015145396A (ja) | 2009-02-27 | 2015-03-24 | Ｂｒｃａ２活性が低下した癌対象の治療のためのｓｎｓ−５９５の使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20120148564A1 (ja) |
| EP (2) | EP2400959A1 (ja) |
| JP (2) | JP5936862B2 (ja) |
| KR (2) | KR20110132400A (ja) |
| CN (2) | CN104688732A (ja) |
| AU (2) | AU2010217796B2 (ja) |
| CA (1) | CA2753261A1 (ja) |
| IL (1) | IL214784A0 (ja) |
| MX (1) | MX348412B (ja) |
| NZ (1) | NZ594829A (ja) |
| RU (1) | RU2558835C2 (ja) |
| SG (2) | SG10201400258SA (ja) |
| WO (1) | WO2010099526A1 (ja) |
| ZA (1) | ZA201106199B (ja) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1725233T3 (pl) | 2004-03-15 | 2011-05-31 | Sunesis Pharmaceuticals Inc | Kompozycja farmaceutyczna zawierająca SNS-595 i jej zastosowanie |
| CN103720701A (zh) | 2007-10-22 | 2014-04-16 | 逊尼希思制药公司 | 在联合治疗中使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸的方法 |
| SG10201504789RA (en) | 2008-12-31 | 2015-07-30 | Sunesis Pharmaceuticals Inc | Method Of Preparing (+)-1,4-Dihydro-7-[(3s,4s)-3methoxy-4-(Methylamino)-1-Pyrrolidinyl]-4-Oxo-1-(2-Thiazolyl)-1,8-Naphthyridine-3-Carboxylic Acid |
| EP2400959A1 (en) * | 2009-02-27 | 2012-01-04 | Sunesis Pharmaceuticals, Inc. | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
| UA110465C2 (en) | 2009-09-04 | 2016-01-12 | Sunesis Pharmaceutecals Inc | Stable sns-595 composition |
| TW201120037A (en) | 2009-10-26 | 2011-06-16 | Sunesis Pharmaceuticals Inc | Compounds and methods for treatment of cancer |
| CA3238399A1 (en) | 2021-12-15 | 2023-06-22 | Torben LUND-HANSEN | Scfv and antibodies with reduced multimerisation |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6024A (en) * | 1849-01-09 | Cast-iron gar-wheel | ||
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| JP3391796B2 (ja) | 1994-06-14 | 2003-03-31 | 大日本製薬株式会社 | 新規化合物、その製法および抗腫瘍剤 |
| JPH10173986A (ja) | 1996-12-16 | 1998-06-26 | Sony Corp | 移動体撮影装置 |
| DK1684736T3 (da) * | 2003-12-01 | 2011-11-21 | Kudos Pharm Ltd | Inhibitorer af DNA-skadereparation til behandling af cancer |
| PL1725233T3 (pl) * | 2004-03-15 | 2011-05-31 | Sunesis Pharmaceuticals Inc | Kompozycja farmaceutyczna zawierająca SNS-595 i jej zastosowanie |
| WO2007028171A1 (en) * | 2005-09-02 | 2007-03-08 | Sunesis Pharmaceuticals, Inc. | Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer |
| MX2008015775A (es) | 2006-06-12 | 2009-04-17 | Sunesis Pharmaceuticals Inc | Compuestos y composiciones para tratamiento de cancer. |
| US7790274B2 (en) | 2006-08-02 | 2010-09-07 | High Impact Technology, Llc | Layered panel structure including self-bonded thermoformable and non-thermoformable layer materials |
| WO2008121132A2 (en) * | 2007-03-30 | 2008-10-09 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for identification, monitoring, and treatment of prostate cancer |
| EP2400959A1 (en) * | 2009-02-27 | 2012-01-04 | Sunesis Pharmaceuticals, Inc. | Methods of using sns-595 for treatment of cancer subjects with reduced brca2 activity |
-
2010
- 2010-03-01 EP EP10707173A patent/EP2400959A1/en not_active Withdrawn
- 2010-03-01 MX MX2011008994A patent/MX348412B/es active IP Right Grant
- 2010-03-01 SG SG10201400258SA patent/SG10201400258SA/en unknown
- 2010-03-01 CA CA2753261A patent/CA2753261A1/en not_active Abandoned
- 2010-03-01 EP EP17179348.2A patent/EP3287126A1/en not_active Withdrawn
- 2010-03-01 JP JP2011552217A patent/JP5936862B2/ja not_active Expired - Fee Related
- 2010-03-01 KR KR1020117022340A patent/KR20110132400A/ko active Application Filing
- 2010-03-01 CN CN201410799921.9A patent/CN104688732A/zh active Pending
- 2010-03-01 SG SG2011061512A patent/SG173855A1/en unknown
- 2010-03-01 NZ NZ594829A patent/NZ594829A/xx not_active IP Right Cessation
- 2010-03-01 AU AU2010217796A patent/AU2010217796B2/en not_active Ceased
- 2010-03-01 KR KR1020177010758A patent/KR20170046193A/ko not_active Application Discontinuation
- 2010-03-01 CN CN2010800172031A patent/CN102405045A/zh active Pending
- 2010-03-01 US US13/203,718 patent/US20120148564A1/en not_active Abandoned
- 2010-03-01 WO PCT/US2010/025737 patent/WO2010099526A1/en active Application Filing
- 2010-03-01 RU RU2011139323/15A patent/RU2558835C2/ru not_active IP Right Cessation
-
2011
- 2011-08-22 IL IL214784A patent/IL214784A0/en unknown
- 2011-08-23 ZA ZA2011/06199A patent/ZA201106199B/en unknown
-
2014
- 2014-09-03 US US14/476,606 patent/US20150202189A1/en not_active Abandoned
-
2015
- 2015-03-24 JP JP2015060900A patent/JP2015145396A/ja active Pending
- 2015-07-30 AU AU2015207901A patent/AU2015207901A1/en not_active Abandoned
-
2016
- 2016-08-10 US US15/233,860 patent/US20170182015A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Topatana et al. | Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation | |
| Hirpara et al. | Metabolic reprogramming of oncogene-addicted cancer cells to OXPHOS as a mechanism of drug resistance | |
| Jo et al. | Novel and highly potent ATR inhibitor M4344 kills cancer cells with replication stress, and enhances the chemotherapeutic activity of widely used DNA damaging agents | |
| Wagner et al. | Senescence as a therapeutically relevant response to CDK4/6 inhibitors | |
| Huang et al. | Palbociclib enhances radiosensitivity of hepatocellular carcinoma and cholangiocarcinoma via inhibiting ataxia telangiectasia–mutated kinase–mediated DNA damage response | |
| JP2012523376A5 (ja) | ||
| Guerra et al. | Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review | |
| Patel et al. | Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition | |
| Magnussen et al. | Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma | |
| Gild et al. | Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells | |
| Baldari et al. | Targeting MKK3 as a novel anticancer strategy: molecular mechanisms and therapeutical implications | |
| US20130330421A1 (en) | Combinations of therapeutic agents for treating melanoma | |
| HRP20191145T1 (hr) | Postupak predviđanja ishoda liječenja s afliberceptom kod pacijenta za kojeg se sumnja da ima rak | |
| Ghorai et al. | Sustained inhibition of PARP-1 activity delays glioblastoma recurrence by enhancing radiation-induced senescence | |
| Cocco et al. | Dual CCNE1/PIK3CA targeting is synergistic in CCNE1-amplified/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo | |
| Wang et al. | DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer | |
| Manic et al. | Control of replication stress and mitosis in colorectal cancer stem cells through the interplay of PARP1, MRE11 and RAD51 | |
| Shor et al. | The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings | |
| Yang et al. | Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer | |
| Lian et al. | Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation | |
| Ma et al. | Inhibition of farnesyltransferase potentiates NOTCH-targeted therapy against glioblastoma stem cells | |
| RU2011139323A (ru) | Способы применения sns-595 для лечения субъектов с онкологическими заболеваниями, имеющих сниженную активность brca2 | |
| Narayanan et al. | Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation | |
| Li et al. | Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma | |
| Miyamoto et al. | Synergistic effects of olaparib and DNA-damaging agents in oesophageal squamous cell carcinoma cell lines |